VA-DXC-TECHNOLOGY
DXC Technology (NYSE: DXC) today introduced an advanced Patient-Centered Care solution, a customizable and personalized-health offering that gives healthcare providers the technology to meet the high expectations of today’s patients — without sacrificing cost containment and clinician satisfaction.
The healthcare industry is experiencing a value-based shift of epic proportions, driven by key external trends like an aging population; the proliferation of chronic diseases; rising healthcare costs; staffing shortages; and digital citizenship creating more informed patients. To elevate the patient experience, improve individual outcomes and create a healthier population, healthcare leaders are seeking new business and integrated care models that merge healthcare and life sciences while empowering patients and providers alike.
To help solve these challenges, DXC Patient-Centered Care provides advanced patient-engagement tools that offer convenient care from anywhere, via phone or tablet, at an affordable price. Backed by DXC’s interoperability, analytics and security products, the solution enables providers to access a continuous stream of patient-care data, helping them put the patient first throughout the continuum of care.
“In the age of ‘Dr. Google’ and same-day Amazon deliveries, patients are increasingly more demanding. They will no longer tolerate half-day waits for discharge instructions that could be delivered in seconds via a chatbot, or receive test results by snail mail when they could be viewed immediately on a mobile app. They expect better value and engagement from caregivers, driving the industry to move from traditional care-delivery models toward a patient-centered journey of care,” said Andrea Fiumicelli, vice president and general manager, Healthcare and Life Sciences , DXC Technology. “Our new Patient-Centered Care solution combines DXC’s industry expertise and leading healthcare technology to equip providers with custom-built, next-generation and coordinated care solutions.”
“The future of connected healthcare is centered around collaboration and care, and today’s busy providers need to find innovative ways to connect with their patients within and beyond the walls of a hospital or clinic,” said Dr. Michael Dahlweid, who recently joined DXC as its new global chief medical officer. “Our goal is to enable care teams to share health information across multiple systems, channels, practices and infrastructures, and aggregate it into a secure, consolidated view of the patient’s history of care. This persona-based access to real-time health data will allow clinicians to make the best possible decisions for their patients’ treatment. With speed, scale, flexibility and continuous innovation, DXC Technology prepares traditional healthcare organizations to become major digital-health enablers.”
The DXC Healthcare Portfolio
Patient-Centered Care is the newest solution in DXC’s extensive healthcare portfolio that is transforming the healthcare industry. The portfolio also includes:
- DXC Open Health Connect , a healthcare platform that helps improve healthcare outcomes by creating a connected ecosystem for patients, providers and payers.
- DXC Healthcare Cloud , a cloud-based solution that reduces complexity and risk while allowing approved parties to securely access applications and data 24/7.
- DXC Healthcare Security Services — for which DXC was recently named a leader in the Everest Group PEAK Matrix Assessment 2020 — to help healthcare providers quickly identify and respond to threats, protect data and patient privacy, and securely manage patient identities stored on-premise or in the cloud.
- DXC Health360 ™ , a cloud-based solution that enables providers and payers to personalize care experiences, deliver quality and increase customer loyalty at a lower cost.
- DXC Life Sciences solutions , which give life sciences organizations — including all 12 U.S. Fortune 500 pharmaceutical companies — the tools they need to accelerate innovation, improve operational efficiencies and reduce time to market for new therapies, devices and medicines.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005372/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom